Compare SFBS & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBS | ORKA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 2014 | N/A |
| Metric | SFBS | ORKA |
|---|---|---|
| Price | $82.85 | $84.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $93.00 | $92.50 |
| AVG Volume (30 Days) | 233.4K | ★ 1.2M |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 21.63 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.30 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | $53.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.20 | $10.97 |
| 52 Week High | $90.64 | $91.00 |
| Indicator | SFBS | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 73.62 |
| Support Level | $82.02 | $27.81 |
| Resistance Level | $83.74 | $91.00 |
| Average True Range (ATR) | 1.70 | 4.67 |
| MACD | 0.32 | 2.31 |
| Stochastic Oscillator | 87.09 | 87.12 |
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.